Company: MBIO
Filing Date: 2025-02-21
Form Type: 8-K
Source: 0001104659-25-016145
Chunk: 0

Company: MUSTANG BIO, INC.
Filing Date: 2025-02-21
Form: 8-K
Item: Item 5.07
Chunk 0
---
Item 5.07.      Submission of Matters to a Vote of Security Holders.  

Effective February 19, 2025, the
holders of a majority of the voting power of the capital stock of Mustang Bio, Inc. (the “ Company”) executed a written consent
authorizing, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of up to an aggregate of 5,475,082 shares of the
Company’s common stock underlining certain outstanding warrants issued by the Company pursuant to (A) that certain engagement letter,
dated as of October 23, 2024 (the “ Engagement Letter”), with H. C. Wainwright & Co., LLC (the “ Placement Agent”)
and (B) that certain Securities Purchase Agreement, dated as of February 5, 2025 (the “ Purchase Agreement”), by and among
the Company and certain accredited investors signatory thereto (the “ Investors”), in an amount equal to or in excess of 20%
of the number of shares of common stock outstanding immediately prior to the issuance of such warrants (collectively, the “ Warrant
Share Issuance”).

The written consent was signed
by the holders of 131,052 shares of the Company’s issued and outstanding common stock and 250,000 shares of the Company’s
issued and outstanding Class  A Preferred Stock. Each share of common stock and Class  A Common Stock entitles the holder thereof
to one vote on all matters submitted to stockholders and each share of Class A Preferred Stock has the voting power of 1.1 times (A) the
number of outstanding shares of common stock plus (B) the whole shares of common stock into which the outstanding shares of Class  A
Common Stock and Class  A Preferred Stock are convertible, divided by the number of outstanding shares of Class A Preferred Stock,
or approximately 8.4 votes per share as of February 19, 2025. Accordingly, the holders of approximately 56% of the voting power of the
Company’s capital stock as of February 19, 2025 signed the written consent approving the Warrant Share Issuance.

Pursuant to rules adopted by the
Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, a definitive information statement on Schedule
14C will be filed with the Securities and Exchange Commission and sent or provided to the stockholders of the Company.

SIGNATURES